MXPA04005277A - DISPOSITIVO MEDICO Y METODO PARA LA INHALACION DE UN FáRMACO EN AEROSOL CON HELIOX. - Google Patents
DISPOSITIVO MEDICO Y METODO PARA LA INHALACION DE UN FáRMACO EN AEROSOL CON HELIOX.Info
- Publication number
- MXPA04005277A MXPA04005277A MXPA04005277A MXPA04005277A MXPA04005277A MX PA04005277 A MXPA04005277 A MX PA04005277A MX PA04005277 A MXPA04005277 A MX PA04005277A MX PA04005277 A MXPA04005277 A MX PA04005277A MX PA04005277 A MXPA04005277 A MX PA04005277A
- Authority
- MX
- Mexico
- Prior art keywords
- heliox
- aerosol
- drug
- gas
- medical device
- Prior art date
Links
- GWUAFYNDGVNXRS-UHFFFAOYSA-N helium;molecular oxygen Chemical compound [He].O=O GWUAFYNDGVNXRS-UHFFFAOYSA-N 0.000 title claims abstract description 204
- 239000003814 drug Substances 0.000 title claims abstract description 120
- 229940079593 drug Drugs 0.000 title claims abstract description 120
- 238000000034 method Methods 0.000 title claims abstract description 74
- 239000000443 aerosol Substances 0.000 claims abstract description 128
- 239000002245 particle Substances 0.000 claims abstract description 79
- 239000007788 liquid Substances 0.000 claims abstract description 20
- 239000012080 ambient air Substances 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims abstract description 16
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 9
- 239000012895 dilution Substances 0.000 claims abstract description 8
- 238000010790 dilution Methods 0.000 claims abstract description 8
- 239000007789 gas Substances 0.000 claims description 113
- 239000006199 nebulizer Substances 0.000 claims description 88
- 238000011282 treatment Methods 0.000 claims description 78
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 53
- 229960002052 salbutamol Drugs 0.000 claims description 53
- 239000001307 helium Substances 0.000 claims description 46
- 229910052734 helium Inorganic materials 0.000 claims description 46
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 claims description 46
- 239000003570 air Substances 0.000 claims description 22
- 229940124630 bronchodilator Drugs 0.000 claims description 22
- 238000004891 communication Methods 0.000 claims description 18
- 210000004072 lung Anatomy 0.000 claims description 18
- 239000003246 corticosteroid Substances 0.000 claims description 14
- -1 cyclometasone Chemical compound 0.000 claims description 14
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 12
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 12
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 12
- 229940125388 beta agonist Drugs 0.000 claims description 11
- 229960004436 budesonide Drugs 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 8
- 229960000676 flunisolide Drugs 0.000 claims description 8
- 229960001664 mometasone Drugs 0.000 claims description 8
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 8
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 8
- 150000003431 steroids Chemical class 0.000 claims description 8
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 206010061876 Obstruction Diseases 0.000 claims description 6
- 230000000241 respiratory effect Effects 0.000 claims description 6
- 239000000168 bronchodilator agent Substances 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 229960005294 triamcinolone Drugs 0.000 claims description 5
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims description 5
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 4
- NBMKJKDGKREAPL-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-CXSFZGCWSA-N 0.000 claims description 4
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 4
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- VQDBNKDJNJQRDG-UHFFFAOYSA-N Pirbuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=N1 VQDBNKDJNJQRDG-UHFFFAOYSA-N 0.000 claims description 4
- HOAKOHHSHOCDLI-TUFAYURCSA-N [(8s,9s,10r,11s,13s,14s,17r)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-sulfanylacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-17-yl] butanoate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CS)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O HOAKOHHSHOCDLI-TUFAYURCSA-N 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 230000001078 anti-cholinergic effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims description 4
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 4
- 229940092705 beclomethasone Drugs 0.000 claims description 4
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 4
- 229960002537 betamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 4
- 229960000585 bitolterol mesylate Drugs 0.000 claims description 4
- HODFCFXCOMKRCG-UHFFFAOYSA-N bitolterol mesylate Chemical compound CS([O-])(=O)=O.C1=CC(C)=CC=C1C(=O)OC1=CC=C(C(O)C[NH2+]C(C)(C)C)C=C1OC(=O)C1=CC=C(C)C=C1 HODFCFXCOMKRCG-UHFFFAOYSA-N 0.000 claims description 4
- 229950001167 butixocort Drugs 0.000 claims description 4
- 229960000265 cromoglicic acid Drugs 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 4
- 229960005309 estradiol Drugs 0.000 claims description 4
- 229930182833 estradiol Natural products 0.000 claims description 4
- 229960002714 fluticasone Drugs 0.000 claims description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 4
- 229960000289 fluticasone propionate Drugs 0.000 claims description 4
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 4
- 229960002848 formoterol Drugs 0.000 claims description 4
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims description 4
- 229960001798 loteprednol Drugs 0.000 claims description 4
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 claims description 4
- LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 claims description 4
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 claims description 4
- 229960004398 nedocromil Drugs 0.000 claims description 4
- 229960002657 orciprenaline Drugs 0.000 claims description 4
- 229960005414 pirbuterol Drugs 0.000 claims description 4
- 229960003387 progesterone Drugs 0.000 claims description 4
- 239000000186 progesterone Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229960000195 terbutaline Drugs 0.000 claims description 4
- 229960003604 testosterone Drugs 0.000 claims description 4
- 229960000707 tobramycin Drugs 0.000 claims description 4
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 4
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 238000000889 atomisation Methods 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- 229960001361 ipratropium bromide Drugs 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- 230000036961 partial effect Effects 0.000 claims description 3
- 229960004017 salmeterol Drugs 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 2
- 229940046044 combinations of antineoplastic agent Drugs 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 229960005139 epinephrine Drugs 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims 2
- 230000006022 acute inflammation Effects 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims 1
- 238000007599 discharging Methods 0.000 claims 1
- 238000012387 aerosolization Methods 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 description 31
- 229910052760 oxygen Inorganic materials 0.000 description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 30
- 208000006673 asthma Diseases 0.000 description 19
- 238000002663 nebulization Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 238000013461 design Methods 0.000 description 14
- 230000029058 respiratory gaseous exchange Effects 0.000 description 12
- 238000009826 distribution Methods 0.000 description 10
- 208000024716 acute asthma Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000005713 exacerbation Effects 0.000 description 8
- 239000012530 fluid Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 201000003883 Cystic fibrosis Diseases 0.000 description 6
- 229960001334 corticosteroids Drugs 0.000 description 6
- 238000000151 deposition Methods 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 210000000115 thoracic cavity Anatomy 0.000 description 6
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005399 mechanical ventilation Methods 0.000 description 5
- 230000009798 acute exacerbation Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 239000003380 propellant Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 229940057282 albuterol sulfate Drugs 0.000 description 3
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical compound OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 229940071648 metered dose inhaler Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 238000002106 pulse oximetry Methods 0.000 description 3
- 230000036387 respiratory rate Effects 0.000 description 3
- 208000023504 respiratory system disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960004631 tixocortol Drugs 0.000 description 3
- YWDBSCORAARPPF-VWUMJDOOSA-N tixocortol Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CS)[C@@H]4[C@@H]3CCC2=C1 YWDBSCORAARPPF-VWUMJDOOSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 208000037874 Asthma exacerbation Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006448 Bronchiolitis Diseases 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000032571 Infant acute respiratory distress syndrome Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010028974 Neonatal respiratory distress syndrome Diseases 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 206010042241 Stridor Diseases 0.000 description 2
- KFVPJMZRRXCXAO-UHFFFAOYSA-N [He].[O] Chemical compound [He].[O] KFVPJMZRRXCXAO-UHFFFAOYSA-N 0.000 description 2
- 229940127225 asthma medication Drugs 0.000 description 2
- 229940124748 beta 2 agonist Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940112141 dry powder inhaler Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 201000002652 newborn respiratory distress syndrome Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000009325 pulmonary function Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013125 spirometry Methods 0.000 description 2
- 238000011301 standard therapy Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 206010037132 Pseudomonal infections Diseases 0.000 description 1
- 208000003826 Respiratory Acidosis Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 208000005279 Status Asthmaticus Diseases 0.000 description 1
- 238000010161 Student-Newman-Keuls test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 description 1
- UYVYDRXVNVNQEA-BJTOFBPUSA-N [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] 4-(acetamidomethyl)cyclohexane-1-carboxylate Chemical compound O=C([C@]1(O)[C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@@H]1C)COC(=O)C1CCC(CNC(C)=O)CC1 UYVYDRXVNVNQEA-BJTOFBPUSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 230000007883 bronchodilation Effects 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008246 gaseous mixture Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960001888 ipratropium Drugs 0.000 description 1
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940075473 medical gases Drugs 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008249 pharmaceutical aerosol Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 description 1
- 229960005332 zileuton Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/06—Sprayers or atomisers specially adapted for therapeutic purposes of the injector type
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
- A61M15/0088—Inhalation chambers with variable volume
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0833—T- or Y-type connectors, e.g. Y-piece
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0208—Oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/025—Helium
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33760901P | 2001-12-05 | 2001-12-05 | |
| PCT/US2002/038492 WO2003049791A1 (en) | 2001-12-05 | 2002-12-04 | Medical device and method for inhalation of aerosolized drug with heliox |
| US10/309,644 US20040234610A1 (en) | 2001-12-05 | 2002-12-04 | Medical device and method for inhalation of aerosolized drug with heliox |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04005277A true MXPA04005277A (es) | 2005-03-31 |
Family
ID=23321240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04005277A MXPA04005277A (es) | 2001-12-05 | 2002-12-04 | DISPOSITIVO MEDICO Y METODO PARA LA INHALACION DE UN FáRMACO EN AEROSOL CON HELIOX. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040234610A1 (enExample) |
| EP (1) | EP1453562B1 (enExample) |
| JP (2) | JP2005511211A (enExample) |
| AT (1) | ATE545442T1 (enExample) |
| AU (1) | AU2002364129B2 (enExample) |
| CA (1) | CA2469347C (enExample) |
| ES (1) | ES2379060T3 (enExample) |
| MX (1) | MXPA04005277A (enExample) |
| WO (1) | WO2003049791A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10256663B3 (de) | 2002-12-04 | 2005-10-13 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Gasentladungslampe für EUV-Strahlung |
| US7263993B2 (en) * | 2003-01-21 | 2007-09-04 | Vanderipe Donald R | Method of use of gas mixtures to achieve washout of nitrogen from the body and mitochondria |
| US20060118118A1 (en) * | 2003-10-29 | 2006-06-08 | Smaldone Gerald C | Drug delivery systems |
| KR101137052B1 (ko) * | 2003-11-17 | 2012-04-24 | 노바르티스 아게 | 인공호흡기 회로에 대한 에어로졸의 효과적인 주입 |
| US20050121025A1 (en) | 2003-12-04 | 2005-06-09 | Gamard Stephan C.F. | Portable gas operating inhaler |
| US20050153946A1 (en) * | 2003-12-24 | 2005-07-14 | Collegium Pharmaceuticals, Inc. | Temperature-stable formulations, and methods of development thereof |
| NZ583929A (en) * | 2004-04-15 | 2012-04-27 | Resmed Ltd | Headgear for delivering gas under poitive pressure characterised by a laminated conduit which passes on either side of a patients head |
| US7036500B2 (en) * | 2004-04-21 | 2006-05-02 | Smiths Medical Asd, Inc. | Nebulizer with auxiliary inlet port |
| US7191776B2 (en) * | 2004-05-10 | 2007-03-20 | Smiths Medical Asd, Inc. | Nebulizer breathing system |
| US8534280B2 (en) | 2007-11-19 | 2013-09-17 | Aeon Research and Technolgy Inc. | Patient interface member for use in an aerosol inhalation system |
| US7841342B2 (en) * | 2005-05-03 | 2010-11-30 | Aeon Research And Technology, Inc. | Interface accessory for use with an aerosol inhalation system |
| US7926484B2 (en) * | 2005-05-03 | 2011-04-19 | Aeon Research And Technology, Inc. | Interface accessory for use with an aerosol inhalation system |
| US7445006B2 (en) * | 2005-05-03 | 2008-11-04 | Dhuper Sunil K | Aerosol inhalation system and interface accessory for use therewith |
| CN100464797C (zh) * | 2005-06-06 | 2009-03-04 | 刘里远 | 灭毒型呼吸辅助治疗机 |
| US20080078389A1 (en) * | 2006-09-29 | 2008-04-03 | Yang Xiao | Heliox delivery system and method with positive pressure support |
| US20080078385A1 (en) * | 2006-09-29 | 2008-04-03 | Yang Xiao | System and method for delivery of medication via inhalation |
| WO2010019467A1 (en) * | 2008-08-12 | 2010-02-18 | Praxair Technology, Inc. | System and method for small particle size drug delivery using hypoxic mixture of helium and oxygen |
| US8393323B2 (en) | 2008-09-30 | 2013-03-12 | Covidien Lp | Supplemental gas safety system for a breathing assistance system |
| US10993879B2 (en) | 2010-02-08 | 2021-05-04 | Shenzhen Evergreen Therapeutics Co., Ltd. | Pulmonary delivery of progestogen |
| US10987361B2 (en) * | 2010-02-08 | 2021-04-27 | Shenzhen Evergreen Therapeutics Co., Ltd. | Treating auto-immune and auto-inflammatory diseases |
| US10231976B2 (en) | 2010-02-08 | 2019-03-19 | Prairie Pharmaceuticals LLC | Methods for the use of progestogen as a glucocorticoid sensitizer |
| US8746241B2 (en) | 2011-10-03 | 2014-06-10 | Sabrina B. Cavendish | Combination MDI and nebulizer adapter for a ventilator system |
| EP2806931B1 (en) | 2012-01-23 | 2019-04-10 | AEON Research and Technology, LLC | Modular pulmonary treatment system |
| US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
| GB2546949B (en) * | 2014-11-25 | 2021-09-22 | Fisher & Paykel Healthcare Ltd | Substance delivery arrangement for gas therapy device |
| PL3445428T3 (pl) * | 2016-04-18 | 2021-11-22 | Inspiring Pty Ltd | Urządzenie dystansowe do inhalatora |
| CN106511065A (zh) * | 2016-12-24 | 2017-03-22 | 黄献 | 一种鼻腔冲洗给药装置 |
| BR112019021988B1 (pt) * | 2017-04-18 | 2024-01-23 | Inspiring Pty Ltd | Dispositivo espaçador para fornecimento de medicamentos via um dispositivo nebulizador |
| MX2021013436A (es) * | 2019-05-05 | 2022-01-24 | Peter Goldman | Metodo y aparato para administrar simultaneamente oxigeno y medicamento en inhaladores de dosis medidas mediante inhalacion. |
| KR102330749B1 (ko) * | 2019-08-09 | 2021-11-25 | 고려대학교 산학협력단 | 기도내 분사장치 |
| WO2021189138A1 (en) * | 2020-03-23 | 2021-09-30 | Khwaja Kosar | Ventilator adaptors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4231973A (en) * | 1978-09-29 | 1980-11-04 | C. R. Bard, Inc. | Nebulizer with variable flow rate control and associated method |
| US4649911A (en) * | 1983-09-08 | 1987-03-17 | Baylor College Of Medicine | Small particle aerosol generator for treatment of respiratory disease including the lungs |
| US5020530A (en) * | 1990-05-07 | 1991-06-04 | Miller Warren C | Inhalation therapy device |
| US5379761A (en) * | 1993-07-21 | 1995-01-10 | Schuler; Manfred | First stage scuba regulator |
| US5429123A (en) * | 1993-12-15 | 1995-07-04 | Temple University - Of The Commonwealth System Of Higher Education | Process control and apparatus for ventilation procedures with helium and oxygen mixtures |
| US5479920A (en) * | 1994-03-01 | 1996-01-02 | Vortran Medical Technology, Inc. | Breath actuated medicinal aerosol delivery apparatus |
| US5653223A (en) * | 1994-09-08 | 1997-08-05 | Pruitt; Michael D. | Accurately controlled portable nebulizer |
| US5586551A (en) * | 1995-07-17 | 1996-12-24 | Hilliard; Kenneth R. | Oxygen mask with nebulizer |
| US5701886A (en) * | 1995-08-07 | 1997-12-30 | Ryatt; Sadie | Treatment non-rebreather assembly and method for delivering oxygen and medication |
| US5694920A (en) * | 1996-01-25 | 1997-12-09 | Abrams; Andrew L. | Inhalation device |
| SE9603804D0 (sv) * | 1996-10-16 | 1996-10-16 | Aga Ab | Sätt och anordning för framställning av en finfördelad aerosol |
| EP1059953B1 (en) * | 1998-03-05 | 2005-09-07 | Zivena, Inc. | Pulmonary dosing system |
| US6363772B1 (en) * | 1999-12-10 | 2002-04-02 | Quadrivium, L.L.C. | System and method for detection of a biological condition |
| US6532956B2 (en) * | 2000-03-30 | 2003-03-18 | Respironics, Inc. | Parameter variation for proportional assist ventilation or proportional positive airway pressure support devices |
| US6340023B2 (en) * | 2000-05-17 | 2002-01-22 | John I. Elkins | Rebreather nebulizer device |
-
2002
- 2002-12-04 MX MXPA04005277A patent/MXPA04005277A/es active IP Right Grant
- 2002-12-04 AT AT02799203T patent/ATE545442T1/de active
- 2002-12-04 CA CA2469347A patent/CA2469347C/en not_active Expired - Fee Related
- 2002-12-04 JP JP2003550840A patent/JP2005511211A/ja not_active Ceased
- 2002-12-04 ES ES02799203T patent/ES2379060T3/es not_active Expired - Lifetime
- 2002-12-04 EP EP02799203A patent/EP1453562B1/en not_active Expired - Lifetime
- 2002-12-04 AU AU2002364129A patent/AU2002364129B2/en not_active Ceased
- 2002-12-04 US US10/309,644 patent/US20040234610A1/en not_active Abandoned
- 2002-12-04 WO PCT/US2002/038492 patent/WO2003049791A1/en not_active Ceased
-
2009
- 2009-04-20 JP JP2009102508A patent/JP2010088864A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CA2469347A1 (en) | 2003-06-19 |
| JP2010088864A (ja) | 2010-04-22 |
| EP1453562B1 (en) | 2012-02-15 |
| ES2379060T3 (es) | 2012-04-20 |
| AU2002364129B2 (en) | 2008-06-05 |
| JP2005511211A (ja) | 2005-04-28 |
| WO2003049791A1 (en) | 2003-06-19 |
| AU2002364129A1 (en) | 2003-06-23 |
| EP1453562A1 (en) | 2004-09-08 |
| US20040234610A1 (en) | 2004-11-25 |
| CA2469347C (en) | 2011-03-29 |
| ATE545442T1 (de) | 2012-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002364129B2 (en) | Medical device and method for inhalation of aerosolized drug with heliox | |
| US6360743B1 (en) | System for dispensing pharmaceutical active compounds | |
| DK2393477T3 (en) | APPLICATION OF A GLUCOCORTICOID COMPOSITION FOR TREATMENT OF HEAVY AND UNCONTROLLED ASTMA | |
| US6250300B1 (en) | System for dispensing pharmaceutically active compounds | |
| JP2005511211A5 (enExample) | ||
| US8834848B2 (en) | Flow and volume regulated inhalation for treatment of severe oral corticosteroid-dependent asthma | |
| US8668901B2 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| Ariyananda et al. | Aerosol delivery systems for bronchial asthma | |
| Arnon et al. | Delivery of micronized budesonide suspension by metered dose inhaler and jet nebulizer into a neonatal ventilator circuit | |
| CN1253509A (zh) | 传送式卤疗方法 | |
| Fink | Aerosol device selection: evidence to practice | |
| Ke et al. | Administration of dry powders during respiratory supports | |
| AU2020268815A1 (en) | Apparatus for simultaneously administering oxygen, and metered dose inhaler medication by inhalation | |
| Barry et al. | Nebuliser therapy in childhood | |
| Everard et al. | In vitro assessment of drug delivery through an endotracheal tube using a dry powder inhaler delivery system. | |
| O'Callaghan et al. | The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers | |
| AU2008202227B2 (en) | Medical device and method for inhalation of aerosolized drug with heliox | |
| HUT76861A (en) | An aerosol product and method for producing those | |
| Everard et al. | An alternative aerosol delivery system for amiloride. | |
| Alberts et al. | Effect of Aerosol Devices and Administration Techniques on Drug Delivery in a Simulated Spontaneously Breathing Pediatric Tracheostomy Model | |
| Ehtezazi et al. | The application of mechanical aerosol delivery systems in an in vitro model of mechanically ventilated neonates | |
| Sly | Aerosol therapy in Australia | |
| Jantz et al. | Bronchodilator Aerosol Delivery in Mechanical Ventilation: Jantz MA, Collop NA Bronchodilator Aerosol Delivery in Mechanical Ventilation Intensive Care Med 1999, 14 166-183 | |
| Wi | Aerosol Delivery: of aerosolized drugs for asthma has the advantages of being site | |
| JPS59500900A (ja) | 薬剤の送出装置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |